Surviving the Blockbuster Syndrome

See allHide authors and affiliations

Science  19 Mar 2004:
Vol. 303, Issue 5665, pp. 1796-1799
DOI: 10.1126/science.303.5665.1796

You are currently viewing the summary.

View Full Text


New technologies have sent drug company R&D costs soaring, but with no corresponding rise as yet in the number of new drugs. Executives are talking about mergers, reorganization, and other ways to kick-start their production engines.